Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.70 |
| ▸ | BRAF | P15056 | 2/20 | 0.69 |
| ▸ | GRK6 | P43250 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1240130 | 1.00 | HTT (1.00) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL23854804 | 0.91 | HSP90AA1 (0.84) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL15783213 | 0.87 | MAPT (0.77) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL11896405 | 0.85 | KDM4E (0.74) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL15783221 | 0.85 | KDM4E (0.74) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL12164235 | 0.84 | MCL1 (0.74) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL9965504 | 0.84 | MCL1 (0.74) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL15781891 | 0.84 | MCL1 (0.73) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL15783261 | 0.82 | MCL1 (0.72) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL15783182 | 0.82 | MCL1 (0.70) | HTTSMN1; SMN2KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103444-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | UNIV OSAKA (JP) | 2026-04-16 | — | — | US | disclosed |
| EP-4599832-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2025-08-13 | — | — | EP | disclosed |
| CN-119968204-A | 8-Hydroxyquinoline compound and use thereof | 国立大学法人大阪大学 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024075815-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103444-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | MYLK2, MYLK, ATP2A1 | HTT 2703/4885SMN1; SMN2 1609/4885KDM4E 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.